Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Adenocarcinoma Clinical Trials

A listing of Adenocarcinoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (11) clinical trials

Trial of Carbon Ion Versus Photon Radiotherapy for Locally Advanced Unresectable Pancreatic Cancer

A significant percentage of patients with incurable pancreatic cancer die with predominantly local disease. Conventional chemoradiotherapy (i.e. using photon therapy) leads to inadequate locoregional control rates, despite concurrent chemotherapy and modern radiation techniques. Carbon ion radiation therapy holds the promise of a novel biological mechanism for eradicating local-only disease (heavy ...


Adujvant CT+CRT vs Adujvant CT After D2 Resection for Locally Advanced Proximal Gastric Adenocarcinoma

Because of its special anatomical structure, local recurrence rate of locally advanced proximal gastric adenocarcinoma is still high after radical operation. As a local/regional therapy, radiotherapy combined with concurrent chemotherapy can kill local residual tumor cells and reduce the risk of local and regional recurrence.


Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations

The trial will enroll up to 20 participants. Following enrollment, participants will be initially treated with olaparib 150mg by mouth twice daily for one month. After one month of therapy, the dose of olaparib will be increased to 300mg by mouth twice daily provided there are no grade 3 or ...


Neoadjuvant Multi-epitope HER2 Peptide Vaccine in Patients With HER2-expressing DCIS

This is an interventional clinical study examining the safety and efficacy of a degenerate subdominant HER2 specific helper T cell epitope vaccine (H2NVAC) in patients with HER2-expressing ductal carcinoma in situ (DCIS). The ultimate goal of this vaccine is to prevent future invasive breast cancer among patients who are diagnosed ...


Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer

A Phase 1/2, open label, multi-center study to evaluate the safety, efficacy and tolerability of KY1044 as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with selected advanced malignancies, who are ineligible for or there are no available therapies known to confer a clinical benefit for their ...


An Immunotherapy Study of Nivolumab Plus Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer

The purpose of this study is to test the effectiveness and safety of nivolumab combined with ipilimumab compared to nivolumab monotherapy in participants with previously untreated kidney cancer that has spread.


ROS1 Targeting With Crizotinib in Advanced E-cadherin Negative ER Positive Lobular Breast Cancer or Diffuse Gastric Cancer Study

This clinical study is looking at whether a drug called crizotinib, which is used in some patients with lung cancer, is effective in a sub-type of breast cancer, called lobular breast cancer. As the majority of lobular breast cancers are oestrogen receptor positive (ER+ve), crizotinib will be combined with a ...


Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian Primary Peritoneal or Fallopian Cancer Before Surgery

PRIMARY OBJECTIVES: I. To determine the feasibility of daily olaparib given in the neoadjuvant setting in women with primary advanced high grade non-mucinous epithelial ovarian, fallopian tube, or primary peritoneal cancer. SECONDARY OBJECTIVES: I. Estimate efficacy of olaparib given in the neoadjuvant setting using response rate (by Response Evaluation Criteria ...

Phase N/A

Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma

It is a trial to compare the efficacy and safety of Albumin-bound Paclitaxel plus S-1 versus Oxaliplatin plus S-1 (SOX) as first-line treatment in advanced or recurrent gastric adenocarcinoma.


Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor

After screening, 9 patients in each cancer type-specific cohort (gallbladder & biliary tract carcinoma; cervical carcinoma; colorectal carcinoma; gastric carcinoma; pancreatic carcinoma; and clear cell renal cancer) will enter stage 1. These patients will receive an initial dose of 400 mg of Andes-1537 twice a week (BIW) for 4 weeks ...